The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis by Gaojun Cai et al.
RESEARCH Open Access
The associations between proprotein
convertase subtilisin/kexin type 9 E670G
polymorphism and the risk of coronary
artery disease and serum lipid levels: a
meta-analysis
Gaojun Cai1*†, Bifeng Zhang2†, Ganwei Shi1, Weijin Weng1, Chunyan Ma1, Yanbin Song1 and Ji Zhang1
Abstract
Background: Studies had investigated the associations between proprotein convertase subtilisin/kexin type 9
(PCSK9) E670G polymorphism and coronary artery disease (CAD) and lipid levels, but the results were controversial.
Thus, we performed this meta-analysis to investigate the association between PCSK9 E670G polymorphism and lipid
levels and the susceptibility to CAD.
Methods: All relevant articles according to the inclusion criteria were retrieved and included in the present
meta-analysis. Odds ratios (ORs) with 95 % confidence interval (CI) were used to analyze the strength of the
association between PCSK9 E670G polymorphism and the susceptibility to CAD. At the same time, the pooled
standardized mean difference (SMD) with 95 % CI was used for the meta-analysis of PCSK9 E670G polymorphism
and lipid levels. The publication bias was examined by using Begg’s funnel plots and Egger’s test.
Results: A total of seventeen studies met the inclusion criteria. For CAD association, the pooled effects indicated
that the G allele carriers had higher risk of CAD than non-carriers in dominant genetic model (OR:1.601, 95 % CI:
1.314–1.951, P < 0.001), as well as in allelic genetic model (OR: 1.546, 95 % CI: 1.301–1.838, P < 0.001). When the
subgroup analysis stratified by ethnicity and HWE was performed, the positive result existed in most of the
subgroups. For lipid levels association, the pooled effects indicated that the G allele carriers had higher TC and
LDL-C levels than the non-carriers (for TC, SMD: 0.126, 95 % CI: 0.023–0.229, P = 0.016; for LDL-C, SMD: 0.170,
95 % CI: 0.053–0.287, P = 0.004, respectively). There was no difference in the levels of TG and HDL-C between the
G carriers and the non-carriers in the whole population (SMD: 0.031, 95 % CI: −0.048–0.110, P = 0.440; SMD: −0.123,
95 % CI: −0.251–0.006, P = 0.061, respectively). When the studies were stratified by ethnicity and type of study, the
G carriers had higher TC levels than the non-carriers (SMD: 0.126, 95 % CI: 0.014–0.238, P = 0.027) in the non-Asian
subgroup. The similar results existed in cohort subgroup. The association between PCSK9 E670G polymorphism and
LDL-C levels was significant in all subgroups. Meanwhile, the G carriers had higher TG levels than the non-carriers
(SMD: 0.113, 95 % CI: 0.012–0.214, P = 0.028) in the case–control subgroup. AG + GG genotypes had lower HDL-C
levels than AA genotype in Asian subgroup (SMD: −0.224, 95 % CI: −0.423– −0.025, P = 0.027) and in case–control
subgroup (SMD: −0.257, 95 % CI: −0.467–−0.048, P = 0.016).
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Conclusions: The present meta-analysis concluded that PCSK9 E670G polymorphism was associated with CAD risk
and lipid levels.
Keywords: Proprotein convertase subtilisin/kexin type 9, Dyslipidemia, Polymorphism, Gene, Coronary artery
disease, Meta-analysis
Background
Coronary artery disease (CAD) is the major manifesta-
tions of atherosclerotic process, which is expected to re-
main one of the leading causes of mortality until at least
2030 [1]. Epidemiological studies demonstrated that ele-
vated serum low-density lipoprotein cholesterol (LDL-C)
levels had consistently been shown to be the risk factors
for the occurrence and development of CAD. In
addition, genetic and other environmental factors are in-
volved in the pathogenesis of CAD [2].
Proprotein convertase subtilisin/kexin type 9 (PCSK9),
originally named neural apoptosis regulated convertase-
1 (NARC-1), is the ninth member of the proprotein con-
vertase family [3]. PCSK9 is mainly expressed in liver,
kidney and intestine. The pro-PCSK9 undergoes auto-
catalytic intramolecular cleavage at FAQ15↓2SIP residue
in endoplasmic reticulum (ER) and Golgi apparatus.
After the auto-catalytic procession, the mature and ac-
tive PCSK9 protein is generated and secreted. By the
catalytic domain, PCSK9 binds to the epidermal growth
factor-like repeat A domain (EGF-A) of LDL receptor
(LDLR) and enhances the degradation of LDLR, which
increases the serum lipid levels and accelerates the
procession of atherosclerosis. Recently, numerous stud-
ies revealed that PCSK9 was closely associated with lipid
levels and the risk of CAD.
The coding gene for human PCSK9 protein is located
on chromosome 1p32.3 and it encompasses 12 exons
and encodes a 692 amino acid glycoprotein. It contains a
signal peptide (1–30), a pro-domain (31–152) and a
catalytic domain (153–451) followed by a cysteine-
histidine rich domain (526–692). The pro-domain acts
as an intramolecular chaperone, which ensures the cata-
lytic domain to fold correctly in the ER.
The mutations of PCSK9 were identified as the cause
of a third monogenetic form of autosomal-dominant
hypercholesterolemia (ADH), except LDLR and apolipo-
protein B (apoB) genes [4]. Recently, there is an increas-
ing interest in the role of the gene polymorphisms of
PCSK9 in the serum lipids homeostasis and the patho-
genesis of CAD.
Up to date, a total of 163 mutations in PCSK9 gene
have been found, including 153 substitutions, eight in-
sertions and two deletion mutations (www.ucl.ac.uk/ldlr/
LOVDv.1.1.0/, the last update February 10, 2011). These
mutations are divided into gain-of-function (GOF) and
loss-of-function (LOF) mutations. LOF mutations in
PCSK9 gene increase the concentration of LDLR on the
cell surface, which promotes the uptake of serum LDL-C
and prevents the procession of CAD.GOF mutations en-
hance the degradation of LDLR, which reduces the up-
takes of LDL-C and ultimately increases the circulating
LDL-C levels. In addition, it may also regulate the pro-
duction and secretion of apoB and enhance the levels of
very low-density lipoprotein (VLDL) [5].
PCSK9 E670G variant (rs505151), a common variant
in exon 12, is located within the cysteine-rich C-
terminal domain, which participates in the regulation of
auto-catalysis [6]. The guanine is substituted for adenine
at nucleotide 23,968, leading to a change from E to G at
the position 670 of the PCSK9 protein, and this change
may increase the affinity of PCSK9 for the LDLR. The
frequency of 670G was varied greatly in different ethnic
populations. Previous studies have revealed that E670G
polymorphism was associated with high levels of total
cholesterol (TC) and LDL-C and the risk of CAD [7, 8],
but the results was inconsistent [9, 10]. For instance,
Slimani A et al. found that the plasma TC and LDL-C
levels were significantly higher in 670G carriers than in
non-carriers and 670G increased the risk and the sever-
ity of CAD [8]. On the contrary, in a Chinese study, this
variant was associated neither with elevated LDL-C
levels, nor with the CAD susceptibility [10].
To enhance statistical power to produce a more pre-
cise result, we performed this meta-analysis based on
available data aimed to derive a more precise association
of the PCSK9 gene polymorphism and lipid levels and
the risk of CAD.
Methods
Studies selection
The meta-analysis followed the Perferred Reporting
Items for Systematic Reviews and Meta-analysis
(Additional file 1: PRISMA) criteria [11]. The electronic
databases, such as PubMed, Foreign Medical Journal
Service (FMJS) and Embase, were searched for relevant
papers on the association between PCSK9 E670G poly-
morphism and serum lipid levels and/or the risk of
CAD. We also searched the Chinese electronic data-
bases, such as Wanfang Data and China National
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Knowledge Infrastructure (CNKI) databases for Chinese
literatures. The following keywords were used in the
search: “PCSK”, “proprotein convertase subtilisin/kexin
type 9”, “neural apoptosis regulated convertase-1”,
“NARC-1”, “polymorphism”, “gene”, “rs505151”, “muta-
tion”, “variant”, “lipid”, “dyslipidemia”, “coronary heart
disease”,“myocardial infarction”, “coronary artery dis-
ease”, “ischemic heart disease”, “acute coronary syn-
drome”, “CAD” and “CHD”. The reference lists of the
relevant papers that we identified were also checked.
Inclusion and exclusion criteria
The eligible study must met the following criteria: 1)
Case–control study or cohort study investigating the re-
lationships between PCSK9 E670G polymorphism and
serum lipid levels and/or the risk of CAD; 2) For the
lipid levels, the data were presented as mean ± standard
deviations (SD) and the study had one of the serum lipid
levels, at least including TC, triglyceride (TG), LDL-C or
high density lipoprotein cholesterol (HDL-C); 3) For risk
of CAD, the frequencies of genotypes in controls and
CAD groups were clear.
Exclusion criteria: 1) The study was not conducted in
human; 2) Family-based study. If there are several mul-
tiple publications from the same population, the most
recent literature with the largest sample size was
adopted.
Data extraction
A special form was prepared for recording the available
information. Two reviewers (Cai and Zhang) independ-
ently extracted the following data from each eligible
study: first author, year of publication, country, ethnicity,
genotype and allele distributions, geontyping method,
lipid levels, type of study, Hardy-Weinberg equilibrium
(HWE). The disagreements were resolved by consulting
with the third author (Shi).
Data analysis
The deviation from the HWE for the PCSK9 E670G
genotype distributions was assessed by Fisher’s exact
test. The odds ratios (ORs) with 95 % confidence inter-
val (CI) were applied to evaluate the strength of the as-
sociation between the PCSK9 E670G polymorphism and
the susceptibility to CAD. Because the frequency of
genotype GG in most of studies was low, the pooled
ORs were only performed for allelic model (G vs. A) and
dominant model (AG +GG vs. AA). The pooled stan-
dardized mean difference (SMD) with 95 % CI was used
for the meta-analysis of PCSK9 E670G polymorphism
and lipid levels. We defined PCSK9 670G carriers as
having the AG and GG genotypes. If the unit of the
lipids is presented as mg/dl, we converted it to mmol/l.
In several studies, the subjects were divided into
different subgroups (e.g. male or female, drinker or non-
drinker, CAD or ischemic stroke), so we treated each
subpopulation as a separate comparison in our meta-
analysis. Between-study heterogeneity was investigated
and measured by using Cochran’s Q test. It was also
detected by using the I2 statistic. If the between-study
heterogeneity was significant (I2 > 50 %, P ≤ 0.05), a
random-effect model (a Dersimonian-Laird method) was
used to calculate the results. Otherwise, the fixed effect
model (a Mantel-Haenszel method) was adopted [12].
Because of the significant heterogeneity among stud-
ies, we carried out sensitivity analysis while evaluating
the results again by omitting one single study each time.
We also performed the subgroup analysis stratified by
ethnicity (“Asian” or “non-Asian”) and type of study
(“case–control” or “cohort”) to explore the sources of
heterogeneity. The publication bias of literature was ex-
amined by Begg’s funnel plots, which was verified by
Egger’s linear regression test.
The STATA version 12.0 (StataCorp LP, College Sta-
tion, Texas 77845 USA) was used for the meta-analysis.
Results
Characteristics of included studies
Through the initial retrieval, a total of 147 records were
selected. 123 records were excluded according to ab-
stract. Full-text articles were retrieved and seven litera-
tures were excluded for the following reasons: (1) data
were repetitive or overlapping (n = 2); (2) data were obvi-
ously wrong (n = 2); (3) data were not obtained (n = 2);
(4) family-based study (n = 1). In the end, 17 literatures
met all the inclusion criteria and are involved in the
present meta-analysis [7, 8, 10, 13–26]. The flow dia-
gram of the study selection process is presented in Fig 1.
All of the eligible studies included in this study had
been approved by the Ethics Committee of their affilia-
tions and our study was approved by the Ethics Com-
mittee of Wujin hospital, affiliated to Jiangsu University.
The characteristics of the included studies were listed
in Tables 1 and 2. For CAD, nine comparisons from
eight articles including 1517 cases and 1795 controls
dealt with the association between PCSK9 E670G poly-
morphism and risk of CAD. All of them were case–con-
trol studies and the minor allelic frequencies (MAF)
varied greatly from 2.3 to 48.3 %. None of the distribu-
tion of genotypes in controls deviated from HWE, ex-
cept Gao et al’s study. Among them, seven studies were
performed among Asians, one among Caucasians and
one among Africans, respectively. The genotyping
method in most studies was PCR-RFLP, except for Mo
et al’s study.
For lipid levels, ten papers separately provided data for
more than one subpopulation (such as male and female
groups, drinker and nondrinker groups, and so on), and
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we treated each subpopulation as a separate comparison.
Therefore, 25 comparisons from 15 papers were used to
evaluate the relationship between PCSK9 E670G poly-
morphism and serum lipid levels, including 14,558 par-
ticipants. Of these, 22 comparisons from 14 papers, 20
comparisons from 13 papers, 21 comparisons from 14
papers and 23 comparisons from 14 papers presented
the data on TC, TG, HDL-C and LDL-C, respectively. 11
comparisons were conducted in Asians, 11 in Cauca-
sians, and 3 in other ethnic populations. Genotype
distributions in 19 populations or subpopulations were
consistent with HWE. Seven papers were case–control
studies and eight papers were cohort studies.
Meta-analysis results
Association of the PCSK9 E670G polymorphism with the risk
of CAD
Due to the rare GG genotype, the dominant and allelic
contrast genetic models were used to evaluate the asso-
ciation of the PCSK9 E670G polymorphism with the risk
Fig. 1 Flow diagram of article selection process for PCSK9 E670G polymorphism and CAD and lipid levels
Table 1 Main characteristics of studies involved in this meta-analysis of PCSK9 E670G polymorphism and CAD risk















(P)AA AG GG AA AG GG
Salazar LA [16] 2007 Chile Caucasian -/ - C-C 110/108 105 5 0 103 5 0 PCR-RFLP 2.3 >0.05
Hsu LA [10] 2009 China Asian 55.6 + 10.5/ 45.9 + 10.4 C-C 202/614 182 20 0 541 72 1 PCR-RFLP 6.0 >0.05
Zeng J [19] 2011 China Asian 65.9 ± 10.2/ 57.0 ± 8.7 C-C 212/184 167 38 7 165 17 2 PCR-RFLP 5.7 >0.05
Meng YH [7] 2011 China Asian 66.49 ± 9.92/ 64.34 ± 15.35 C-C 165/180 146 19 0 166 14 0 PCR-RFLP 3.9 >0.05
Slimani A [8] 2014 Tunisian African 61[55–67]/ 49[45–55] C-C 192/232 148 37 7 199 32 1 PCR-RFLP 7.3 >0.05
Zhang L [23] 2014 China Asian 59.85 + 8.71/ 58.83 + 9.35 C-C 416/257 291 117 8 212 42 3 PCR-RFLP 15.3 >0.05
Mo YQ [26] 2015 China Asian 56.4 + 11.7/ 54.7 + 10.2 C-C 100/100 87 13 0 92 8 0 DNA
sequencing
4.0 >0.05
Gao Y a [25] 2015 China Asian -/- C-C 60/60 19 21 20 20 22 18 PCR-RFLP 48.3 <0.05
Gao Y b [25] 2015 China Asian -/- C-C 60/60 15 21 24 23 18 19 PCR-RFLP 46.7 <0.05
aChinese Han population
bMongols population
C-C case–control, PCR-RFLP polymerase chain reaction- restriction fragment length polymorphism, MAF minor allelic frequencies, HWE Hardy-Weinberg equilibrium
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Table 2 Characteristics of individual studies included in the meta-analysis of PCSK9 E670G polymorphism and lipid levels




TC (mmol/l) TG (mmol/l) HDL-C (mmol/l) LDL-C (mmol/l) Genotyping
methodM SD M SD M SD M SD
Chen SN 1 [13] 2005 American Mixed Cohort LCAS
population
AA 324 5.69 0.62 1.83 0.64 1.14 0.29 3.72 0.51 Allelic
discrimination
assays
AG + GG 48 5.82 0.66 1.66 0.63 1.16 0.31 3.89 0.57
Chen SN 2 [13] 2005 American Caucasian Cohort TexGen
population
AA 292 NA NA NA NA NA NA 2.28 0.65 Allelic
discrimination
assays
AG + GG 27 NA NA NA NA NA NA 2.43 0.55
Evans D 1 [14] 2006 Germany Caucasian Cohort Male group AA 190 6.05 1.4 1.39 0.45 1.16 0.31 4.29 1.34 PCR-RFLP
AG + GG 26 6.57 1.48 1.55 0.44 1.2 0.29 4.65 1.37
Evans D 2 [14] 2006 Germany Caucasian Cohort Female group AA 210 6.83 1.45 1.32 0.45 1.55 0.44 4.65 1.45 PCR-RFLP
AG + GG 18 6.65 1.47 1.22 0.23 1.58 0.52 4.5 1.37
Scartezini M [15] 2007 UK Caucasian Cohort NPHSII men AA 930 5.73 0.99 NA NA 0.81 0.24 3.98 0.94 PCR-RFLP
AG + GG 135 5.65 0.96 NA NA 0.83 0.26 3.92 0.94
Polisecki E 1 [17] 2008 American Caucasian Cohort Male group AA 2455 5.25 0.03 NA NA NA NA 3.47 0.03 Taqman
AG + GG 165 5.26 0.06 NA NA NA NA 3.47 0.06
Polisecki E 2 [17] 2008 American Caucasian Cohort Female group AA 2638 5.71 1.73 NA NA NA NA 3.73 1.59 Taqman
AG + GG 158 5.85 0.95 NA NA NA NA 3.84 0.84
Hsu LA 1 [10] 2009 Taiwan Asian C-C CAD group AA 541 5.14 0.96 1.59 1.3 1.42 0.37 3.02 0.85 PCR-RFLP
AG 73 4.95 0.96 1.72 1.53 1.44 0.36 2.78 0.82
Hsu LA 2 [10] 2009 Taiwan Asian C-C Control group AA 182 5.29 1.31 2.32 2.07 1.04 0.27 3.25 1.17 PCR-RFLP
AG 20 5.28 0.74 2.48 1.4 1.07 0.33 3.41 0.6
Norata GD 1 [18] 2010 Italy Caucasian Cohort PLIC study AA 1466 5.71 0.98 1.2 0.79 1.42 0.38 3.74 0.9 Taqman
AG + GG 75 5.99 1.2 1.16 0.58 1.45 0.35 4.01 1.07
Norata GD 2 [18] 2010 Italy Caucasian Cohort Ventimiglia
study
AA 728 4.76 0.99 NA NA NA NA 3.02 0.86 Taqman
AG + GG 48 4.89 0.98 NA NA NA NA 3.23 0.87
Zeng J [19] 2011 China Asian C-C CAD group AA 167 3.73 0.8 1.5 0.59 1.26 0.38 2.16 0.73 PCR-RFLP
AG + GG 45 4.25 1.38 1.87 1.16 1.26 0.41 2.58 1.08
Meng YH [7] 2011 China Asian C-C CAD group AA 146 4.41 0.72 0.99 0.62 1.48 0.51 2.22 0.63 PCR-RFLP
AG 19 4.63 1.21 1.17 0.97 0.98 0.84 3.02 0.97
Aung LHH 1 [21] 2013 China Asian Cohort non-drinker
group
AA 744 4.59 0.99 1.23 0.92 1.82 0.49 2.55 0.82 PCR-RFLP















Table 2 Characteristics of individual studies included in the meta-analysis of PCSK9 E670G polymorphism and lipid levels (Continued)
Aung LHH 2 [21] 2013 China Asian Cohort Drinker group AA 543 4.84 1.07 1.02 0.73 1.74 0.44 2.94 0.81 PCR-RFLP
AG 24 4.55 0.64 1.1 0.58 1.63 0.5 2.69 0.44
Mayne J [20] 2013 Canada Caucasian Cohort African
Canadian
population
AA 192 5.56 1.14 1.59 0.77 1.2 0.4 3.64 1.01 PCR + full
exonic
sequencing
AG 15 5.11 1.12 1.27 0.48 1.1 0.3 3.45 1.11
Slimani A 1 [8] 2014 Tunisian African C-C CAD group AA 148 NA NA 1.69 0.86 1 0.36 NA NA PCR-RFLP
AG + GG 44 NA NA 1.97 0.96 1.03 0.16 NA NA
Slimani A 2 [8] 2014 Tunisian African C-C IS group AA 90 NA NA 1.58 0.75 1.35 0.4 NA NA PCR-RFLP
AG + GG 24 NA NA 1.47 0.58 1.04 0.19 NA NA
Anderson JM 1 [22] 2014 Brazil Caucasian C-C HC group AA 91 7.21 0.96 1.87 0.8 1.45 0.36 4.89 0.88 Taqman
AG + GG 37 7.4 0.96 1.81 0.76 1.5 0.31 4.94 0.8
Anderson JM 2 [22] 2014 Brazil Caucasian C-C NL group AA 131 4.47 0.47 0.91 0.32 1.53 0.36 2.53 0.47 Taqman
AG + GG 40 4.5 0.49 0.95 0.3 1.47 0.26 2.59 0.47
Zhang L 1 [23] 2014 China Asian C-C CAD group AA 291 4.07 1.16 1.82 0.79 1.37 0.16 2.29 0.77 PCR-RFLP
AG + GG 125 4.49 1.31 1.87 1.09 1.31 0.25 2.5 0.74
Zhang L 2 [23] 2014 China Asian C-C Control
group
AA 212 4.67 0.62 1.45 1.16 1.49 0.21 2.67 0.81 PCR-RFLP
AG 45 4.53 0.33 1.37 0.88 1.4 0.21 2.63 0.8
Jeenduang N 1 [24] 2015 Thai Asian Cohort Male group AA 132 5.54 1.3 1.46 0.84 1.32 0.35 3.66 1.13 PCR-RFLP
AG 3 5.82 2.25 1.4 0.92 1.19 0.21 4 2.06
Jeenduang N 2 [24] 2015 Thai Asian Cohort Female
group
AA 347 5.54 1.22 1.22 0.74 1.45 0.34 3.62 0.95 PCR-RFLP
AG 13 5.99 0.94 1.01 0.35 1.49 0.23 4.04 0.94
Mo YQ [26] 2015 China Asian C-C CAD group AA 87 4.48 0.81 0.97 0.58 1.49 0.47 2.12 0.72 DNA
sequencing
AG 13 4.56 0.97 1.05 0.89 0.97 0.73 3.01 0.83
















of CAD. Because of absence of significant between-study
heterogeneity, the fixed-effect model was applied. The
pooled effects indicated that the G allele carriers had
higher risk of CAD than non-carriers in dominant
model (OR:1.601, 95 % CI: 1.314–1.951, P < 0.001), as
well as in allelic model (OR: 1.546, 95 % CI: 1.301-1.838,
P < 0.001) (Table 3, Fig. 2a, b).
Then the subgroup analyses stratified by ethnicity and
HWE were performed. In the subgroup analyses strati-
fied by ethnicity, significant associations were found
among both Asians (for dominant model, OR: 1.590,
95 % CI: 1.278–1.978, P < 0.001; for allelic model, OR:
1.503, 95 % CI: 1.244–1.816, P < 0.001) and non-Asians
(for dominant model, OR: 1.652, 95 % CI: 1.040–2.626,
P = 0.034; for allelic model, OR: 1.788, 95 % CI: 1.166–
2.743, P = 0.008). Subgroup analysis was also performed
by HWE, significant association only existed in subgroup
in HWE (for dominant model, OR: 1.633, 95 % CI:
1.321–2.018, P < 0.001; for allelic model, OR: 1.627, 95 %
CI: 1.335–1.983, P < 0.001), suggesting that the results
are credible.
Association of the PCSK9 E670G polymorphism with
serum lipid levels
As shown in Table 4, in the whole population, the
pooled effects indicated that the G allele carriers had
higher TC and LDL-C levels than the non-carriers (for
TC, SMD: 0.126, 95 % CI: 0.023–0.229, P = 0.016; for
LDL-C, SMD: 0.170, 95 % CI: 0.053–0.287, P = 0.004, re-
spectively) (Fig. 3a, b). There was no difference in the
levels of TG and HDL-C between the G carriers and the
non-carriers in the whole population (SMD: 0.031, 95 %
CI: -0.048–0.110, P = 0.440; SMD: -0.123, 95 % CI:
-0.251–0.006, P = 0.061, respectively) (Fig. 3c, d).
The subgroup analyses stratified by ethnicity and type
of study were also performed. In the non-Asian sub-
group, the G carriers had higher TC levels than the non-
carriers (SMD: 0.126, 95 % CI: 0.014-0.238, P = 0.027).
The similar results existed in cohort subgroup. The as-
sociation between PCSK9 E670G polymorphism and
LDL-C levels was significant in all subgroups. Mean-
while, the G carriers had higher TG levels than the non-
carriers (SMD: 0.113, 95 % CI: 0.012-0.214, P = 0.028) in
the case–control subgroup. AG +GG genotypes had
lower HDL-C levels than AA genotype in Asian sub-
group (SMD: -0.224, 95 % CI: -0.423- -0.025, P = 0.027)
and in case–control subgroup (SMD: -0.257, 95 % CI:
-0.467–0.048, P = 0.016).
Heterogeneity analysis
For CAD, the between-study heterogeneity was not sig-
nificant (for dominant model, I2 = 30.4 %, P = 0.175; for
allelic model, I2 = 36.3 %, P = 0.128). For lipid levels,
there was significant heterogeneity among the total com-
parisons for TC, HDL-C and LDL-C (for TC, I2 = 57.4 %,
Pheterogeneity < 0.001; for HDL-C, I
2 = 63.7 %, Pheterogeneity
< 0.001; for LDL-C, I2 = 68.2 %, Pheterogeneity < 0.001). In
order to explore the possible sources of heterogeneity,
subgroup analyses stratified by ethnicity (Asian or non-
Asian) and type of study (cohort or case–control) were
performed. But the between-study heterogeneity was not
obviously reduced under the subgroup analyses.
Sensitivity analysis
To evaluate the influence of single study on the
whole result, the sensitivity analysis was carried out
by calculating pooled estimates again when omitting a
single study each time. The results suggested that no
single study could influence the stability of the overall
pooled estimates not only for CAD, but also for lipid
levels (Additional file 2: Figure S1A-E).
Publication bias
The Begg’s funnel plot was performed to assess the pub-
lication bias and no visual publication bias was found in
all the comparisons, which was confirmed by Egger’s test
(for CAD: P = 0.095; for TC: P = 0.143; for TG: P = 0.585;
for HDL-C: P = 0.295; for LDL-C: P = 0.464, respectively)
(Additional file 3: Figure S2A-E).
Table 3 Summary of meta-analysis of association of PCSK9 E670G polymorphism and CAD risk
N n (CAD/
controls)
Dominant model Allelic model
OR (95 % CI) POR I
2 (%) PQ OR (95 % CI) POR I
2 (%) PQ
All 9 1517/1795 1.601 (1.314–1.951) <0.001 30.4 0.175 1.546 (1.301–1.838) <0.001 36.3 0.128
Ethnicity
Asians 7 1215/1455 1.590 (1.278–1.978) <0.001 44.0 0.098 1.503 (1.244–1.816) <0.001 45.5 0.088
non-Asians 2 302/340 1.652 (1.040–2.626) 0.034 0.0 0.386 1.788 (1.166–2.743) 0.008 0 0.318
HWE
P > 0.05 7 1397/1675 1.633 (1.321–2.018) <0.01 41.7 0.11 1.627 (1.335–1.983) <0.001 43.6 0.100
P < 0.05 2 120/120 1.411 (0.819–2.430) 0.215 0 0.327 1.306 (0.912–1.869) 0.145 0 0.360
OR odds ratio, CI confidence interval, POR p values for odds ratio, PQ p values for heterogeneity form Q-test, HWE Hardy-Weinberg equilibrium, N number of study,
n number of individuals
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Fig. 2 Forest plot of the association between PCSK9 E670G polymorphism and the risk of CAD (a): dominant genetic model, AG + GG vs AA; (b):
allelic genetic model, G vs A)
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Table 4 Summary of meta-analysis of association of PCSK9 E670G polymorphism and lipid levels

























































0.027 46.5 0.044 9/3169 −0.024
(−0.142–0.094)
0.688 41.5 0.090 104234 −0.017
(−0.165–0.132)










0.034 53.9 0.011 9/4411 −0.097
(−0.222–0.029)



















0.016 74.3 <0.001 9/2265 0.307
(0.027–0.588)
0.031 83.3 <0.001
C-C case–control, SMD standardized mean difference, CI confidence interval, POR p values for odds ratio, PQ p values for heterogeneity form Q-test, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein
















To our knowledge, the current meta-analysis was the
first study to investigate the relationships between
PCSK9 gene E670G polymorphism and lipid levels and
the risk of CAD. Our study concluded that PCSK9
E670G polymorphism might be associated with lipid
levels and the susceptibility to CAD.
A growing body of evidence indicated that PCSK9
might influence the serum lipid levels and the progres-
sion of atherosclerosis in vitro and in vivo. Through a
post-transcriptional pathway, PCSK9 regulates the level
of LDLR and then plays a major role in cholesterol
homeostasis. In addition to the degradation of LDLR,
PCSK9 may also have a potential effect on the apoB100,
which may be another factor to atherosclerosis. The
monoclonal antibodies of PCSK9 are going to the phase
III clinical trials, which are expected to be the new hope
for the patients with ADH.
In 2003, Abifadel et al. [27] firstly identified the
mutation in the PCSK9 gene. Since then, a large
number of LOF and GOF mutations were reported.
Among them, E670G, as the GOF mutation, is one of
the most commonly investigated PCSK9 gene poly-
morphisms. The association of PCSK9 genetic poly-
morphism with the disorders of lipid profile and risk
of CAD has been intensively studied, but the results
are inconclusive [9, 13–15, 18, 26, 28]. Even in the
same ethnic population, the results were also incon-
sistent [7, 10, 21]. The discrepancies of the associa-
tions between PCSK9 E670G polymorphism and lipid
levels and CAD among various populations may be
due to the different characteristics of the study
Fig. 3 Forest plot of the associations between PCSK9 E670G polymorphism and lipid levels. (a): for TC levels, random-effect model; (b): for LDL-C
levels, random-effect model; (c): for TG levels, fixed effect model; (d): for HDL-C levels, random-effect model)
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population, such as age, gender, ethnicity and/or en-
vironmental factors [29]. In addition, a small sample
size may also be one cause. To diminish these influ-
ences, we retrieved all the relevant articles and ana-
lyzed the potential associations between PCSK9
E670G polymorphism and lipid levels and susceptibil-
ity to CAD. The present meta-analysis showed that
670G carriers had higher levels of TC and LDL-C
than non-carriers and higher risk of CAD in overall
populations (SMD: 0.126, 95 % CI: 0.023-0.229, P =
0.016; SMD: 0.170, 95 % CI: 0.053-0.287, P = 0.004,
respectively). The dominant model suggested that
670G carriers were at a 1.601-fold higher risk of
CAD than non-carriers. In the whole population,
there was no difference in the levels of TG and HDL-
C between the 670G carriers and non-carriers.
For the lipid study, there was a significant between-
study heterogeneity, which may affect the interpretation
of the results. To explore the heterogeneity, the sub-
group analyses stratified by ethnicity and type of study
were performed. But, we still could not explain the
source of heterogeneity entirely. In the subgroup ana-
lyses, we found that 670G carriers had high TC levels in
non-Asian populations (SMD: 0.126, 95 % CI: 0.014-
0.238, P = 0.027) and in cohort studies (SMD: 0.133,
95 % CI: 0.010-0.256, P = 0.034). The association be-
tween this mutation and LDL-C levels was significant in
all subgroups. Interestingly, the 670G carriers had higher
TG levels in case–control subgroup (SMD: 0.113, 95 %
CI: 0.012-0.214, P = 0.028). Moreover, the 670G carriers
had lower HDL-C levels in Asian population (SMD:
-0.224, 95 % CI: -0.423- -0.025, P = 0.027) and case–con-
trol subgroup (SMD: -0.257, 95 % CI: -0.467- -0.048, P =
0.016). The sensitivity analysis found that the pooled ef-
fects did not change after excluding single study each
time, which indicated that the results were stable.
As other meta-analyses, there were several inherent
limitations in this study. Firstly and mainly, the
between-study heterogeneity is significant, which was a
potential problem that may affect the interpretation of
the results. As we all know, the between-study hetero-
geneity may be influenced by age, sex, sample size, type
of study, and so on. Although the subgroup analyses
were performed, the heterogeneity was not explained en-
tirely. Secondly, the relationships between this SNP and
CAD risk and lipid levels did not consider the confound-
ing factors, such as age, sex, smoking, drinking and
other lifestyle factors. In the study conducted by Evans
et al, E670G polymorphism was associated with in-
creased LDL-C levels in man but not in women. Thirdly,
the number of studies included in the meta-analysis was
small for CAD risk. Only one study was conducted in
Caucasian population and one study was in African
population. Fourthly, although the Egger’s tests indicated
no remarkable publication bias in our meta-analysis, the
inevitable publication bias may remain in the results be-
cause the papers having negative result were probably
more difficult to be accepted for publication. Finally, the
present meta-analysis was not able to assess gene-gene
and gene-environment interactions.
Conclusions
Despite the limitations, the present meta-analysis con-
cluded that PCSK9 E670G polymorphism was associated
with CAD risk and lipid levels.
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